Compare Heron Therapeutics Inc (HRTX) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Uranium Energy Corp — how do they compare? Heron Therapeutics Inc trades at $0.48 (market cap $91.46M), while Uranium Energy Corp trades at $9.55 (market cap $4.65B). The key difference: Uranium Energy Corp is far larger — about 50.8× Heron Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| HRTX | UEC | |
|---|---|---|
Market Cap | $91.46M | $4.65B |
Sector | Health | Energy |
52-Week High | $1.96 | $20.14 |
52-Week Low | $0.39 | $8.00 |
Enterprise Value | $189.36M | $4.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
UEC trades at $9.40, up 1.29% today, but faces bearish technical signals with 18 sell indicators against 2 buys. The company reported a net loss of $87.66 million in 2025 on $66.84 million revenue, with a negative net margin of -513.24% in 2026. Recent news highlights operational challenges, including zero sales in Q3 2026 and wider losses, though strategic assets and $794 million liquidity offer some stability.
Despite analyst consensus favoring buys (87.5%), high execution risks and persistent losses temper near-term optimism. Investment appeal hinges on successful production ramp-up and uranium price recovery, but volatility and cost pressures present significant downside risks for stockholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
